Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 12.33 -2.99% -0.38
CHRS closed down 2.99 percent on Friday, October 19, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CHRS trend table...

Date Alert Name Type % Chg
Oct 19 Wide Bands Range Expansion 0.00%
Oct 19 Down 3 Days in a Row Weakness 0.00%
Oct 19 Oversold Stochastic Weakness 0.00%
Oct 18 Hammer Candlestick Bullish -2.99%
Oct 18 Wide Bands Range Expansion -2.99%
Oct 18 Oversold Stochastic Weakness -2.99%
Oct 17 Wide Bands Range Expansion -5.08%
Oct 17 Oversold Stochastic Weakness -5.08%
Oct 16 Outside Day Range Expansion -7.85%
Oct 16 Wide Bands Range Expansion -7.85%

Older signals for CHRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Is CHRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.66
52 Week Low 8.05
Average Volume 567,450
200-Day Moving Average 14.392
50-Day Moving Average 17.0116
20-Day Moving Average 14.629
10-Day Moving Average 13.205
Average True Range 0.8304
ADX 41.57
+DI 8.612
-DI 28.3905
Chandelier Exit (Long, 3 ATRs ) 14.7588
Chandelier Exit (Short, 3 ATRs ) 14.5312
Upper Bollinger Band 17.6345
Lower Bollinger Band 11.6235
Percent B (%b) 0.12
BandWidth 41.089617
MACD Line -1.2607
MACD Signal Line -1.1321
MACD Histogram -0.1285
Fundamentals Value
Market Cap 633.1 Million
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -4.74
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.67
Resistance 3 (R3) 13.72 13.32 13.44
Resistance 2 (R2) 13.32 12.98 13.30 13.37
Resistance 1 (R1) 12.83 12.77 12.63 12.78 13.29
Pivot Point 12.43 12.43 12.34 12.41 12.43
Support 1 (S1) 11.94 12.09 11.74 11.89 11.37
Support 2 (S2) 11.54 11.88 11.52 11.29
Support 3 (S3) 11.05 11.54 11.22
Support 4 (S4) 11.00